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Objectives Because current guidelines recognise high-grade anal squamous intraep-
ithelial lesions (HSILs) and low-grade SILs (LSILs), and recommend treatment of
all HSILs although not all progress to cancer, this study aims to distinguish trans-
forming and productive HSILs by grading immunohistochemical (IHC) biomark-
ers p16INK4a (p16) and E4 in low-risk human papillomavirus (lrHPV) and high-
risk (hr)HPV-associated SILs as a potential basis for more selective treatment.
Methods Immunostaining for p16 and HPV E4 was performed and graded in 183
biopsies from 108 HIV-positive men who have sex with men. The causative HPV
genotype of the worst lesion was identified using the HPV SPF10-PCR-DEIA-LiPA25
version 1 system, with laser capture microdissection for multiple infections. The
worst lesions were scored for p16 (0–4) to identify activity of the hrHPV E7 gene,
and panHPV E4 (0–2) to mark HPV production and life cycle completion.
Results There were 37 normal biopsies, 60 LSILs and 86 HSILs, with 85% of LSILs
caused by lrHPV and 93% of HSILs by hrHPV. No normal biopsy showed E4, but
43% of LSILs and 37% of HSILs were E4 positive. No differences in E4 positivity rates
were found between lrHPV and hrHPV lesions. Most of the lesions caused by lrHPV
(90%) showed very extensive patchy p16 staining; p16 grade in HSILs was variable,
with frequency of productive HPV infection dropping with increasing p16 grade.
Conclusions Combined p16/E4 IHC identifies productive and nonproductive HSILs
associated with hrHPV within the group of HSILs defined by the Lower Anogeni-
tal Squamous Terminology recommendations. This opens the possibility of inves-
tigating selective treatment of advanced transforming HSILs caused by hrHPV,
and a ‘wait and see’ policy for productive HSILs.
What’s already known about this topic?
• For preventing anal cancer in high-risk populations, all patients with high-grade
squamous intraepithelial lesions (HSILs) are treated, even though this group of
lesions is heterogeneous, the histology is variable and regression is frequent.
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What does this study add?
• By adding human papillomavirus (HPV) E4 immunohistochemistry to p16 INK4a
(p16), and grading expression of both markers, different biomarker expression pat-
terns that reflect the heterogeneity of HSILs can be identified.
• Moreover, p16/E4 staining can separate high-risk HPV-associated HSILs into pro-
ductive and more advanced transforming lesions, providing a potential basis for
selective treatment.
The incidence of squamous cell carcinoma of the anal canal
and anal intraepithelial neoplasia (AIN), also called squamous
intraepithelial lesions (SILs), is increasing, especially in high-
risk populations such as men who have sex with men (MSM),
HIV-infected (HIV+) patients, and women with a history of a
vulvar or cervical human papillomavirus (HPV)-related malig-
nancy.1–3 High-risk (hr)HPV is detected in over 80% of anal
cancers,4–8 while carcinoma associated with low-risk (lr)HPV
is rare.9 Because of the similarities in aetiology and pathology
between cervical intraepithelial neoplasias (CINs) and AINs,
the clinical approaches to these lesions are similar. In the case
of suspected anal high-grade SILs (HSILs), patients are sub-
jected to a high-resolution anoscopy (HRA) during which
biopsies are taken of abnormal appearing regions; treatment
follows after confirming diagnosis of HSILs by histopathology,
which has low inter- and intraobserver agreement.10,11
The Lower Anogenital Squamous Terminology (LAST) rec-
ommendations recognise only HSILs and low-grade SILs
(LSILs).12 This separation is based on the assumption that
LSILs represent a productive HPV infection that will regress,
whereas HSILs are considered to represent a transforming HPV
infection that has a high chance of progression to cancer and
is in need of treatment. However, it is estimated that only
10% of anal HSILs ultimately progress to cancer7 if left
untreated, and about 47% show regression.13,14 The LAST rec-
ommendations for pathological diagnosis make only limited
use of immunohistochemical (IHC) biomarkers. The recom-
mendations state that diagnosis of HSILs should be made using
haematoxylin and eosin (HE) histopathology, supported by
the use of p16INK4a (p16) as a surrogate marker for hrHPV E7
transforming gene activity only to confirm HSIL diagnosis in
case of uncertainty or disagreement about LSIL vs. HSIL to
show presence of diffuse p16 positivity.12
A biomarker specific for productive HPV infection, such as
HPV E4, in combination with patterns of diffuse p16 expres-
sion as a marker of the transforming activity of the hrHPV E7
gene, might help to classify more objectively AINs, both LSILs
and HSILs, and provide a basis for more selective treatment,
avoiding unnecessary intervention for self-limiting lesions.
Currently, the LAST recommendations recommend that all
HSILs be treated. There are several treatment modalities for
anal HSILs, including infrared coagulation, electrocautery, sur-
gical excision and topical application of trichloroacetic acid or
imiquimod. Currently, electrocautery is the treatment of
choice for intra-anal HSILs in many centres.15 However, there
is no international consensus guideline, recurrence rates are
high for all modalities, and all can cause side-effects such as
pain and anal blood loss.16 Selective treatment of only those
HSILs with a higher chance of progression to cancer could
prevent overtreatment and negative side effects.
E4 is a marker of completion of the HPV life cycle seen in
productive HPV infection associated with low-grade CIN or
AIN.17,18 Expression of E4 in HPV-infected differentiated squa-
mous cells results in disruption of the cell’s keratin filamen-
tous network, inhibits formation of the cornified envelope
and plays a role in virus release and transmission.19
p16 is diffusely overexpressed in high-grade intraepithelial
lesions and carcinomas driven by hrHPV, and is induced by
HPV E7 of hrHPV types.12,20,21 It is a protein regulating the
G1 to S phase checkpoint of the cell cycle.
Previously we have shown that the high-grade AIN2 and
AIN3 differ from each other in expression of abundant E4,
and no HPV E4 was found in AIN3 lesions.22 In this study we
demonstrate the heterogeneity of HSILs using a combination
of IHC biomarkers p16 and E4 within the category of HSILs
defined by current practice using LAST recommendations.12
We determine the causative HPV genotype of SILs and relate
the HPV genotype to the p16 and HPV E4 biomarker expres-
sion pattern to show that, based on patterns of biomarker
expression of p16/E4, we can identify productive HSILs asso-
ciated with hrHPV and SILs associated with lrHPV. This pro-
vides a potential basis for selection of cases currently treated
as HSILs that could be appropriate for a ‘wait and see’ policy
and not require immediate treatment.
Materials and methods
Study population
For the present study, 183 biopsies from two studies were used.
For the first group, biopsies from the H2M2 cohort study were
selected.23 H2M2 is a multicentre prospective cohort study of
HIV+ MSM aged ≥ 18 years, conducted at several clinics in Ams-
terdam. Men had anal HPV testing every 6 months for 2 years,
and in the course of regular care they were offered anal screen-
ing using HRA. At the initial HRA, biopsies were taken from
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HSIL-suspected areas, detecting a HSIL in at least one biopsy in
50 men. All other biopsies from these 50 men were also
included, resulting in a total number of 116 biopsies.
A second group was selected from the pathology files of the
New York Presbyterian Hospital. This group consisted of 67
biopsies from 53 MSM of whom 47 were HIV+. Of the 67
biopsies, 60 were from HIV+ MSM. Biopsies from this second
group had been previously stained with biomarkers p16, Ki-
67 and E4 for description of expression patterns in different
grades of AIN.22
Histology processing and review
The formalin-fixed paraffin-embedded (FFPE) material of all
included biopsies was cut at DDL Diagnostic Laboratory, Rijs-
wijk, the Netherlands. Subsequent slides were used for 4-lm
slides for haematoxylin and eosin (HE) staining (before and
after), three 4-lm slides for IHC staining (p16 and E4), one
membrane slide for laser capture microdissection (LCM), and
one tube (3 9 8 lm) for HPV detection.
Two specialized pathologists reviewed the HE slide, first
individually and then together, to make a consensus diagnosis.
Then, the p16 slide was used to confirm detection of HSILs in
a set of AIN1 and all AIN2, in an approach based on the LAST
recommendations: histologically normal: normal; histologi-
cally AIN1 (no suspicion of AIN2): LSIL; histologically AIN1
(suspicion of AIN2 by at least one pathologist) or AIN2, p16
negative: LSIL; histologically AIN1 (suspicion of AIN2 by at
least one pathologist) or AIN2 and p16 diffusely positive:
HSIL; consensus diagnosis AIN3: HSIL.
In further analyses, the consensus diagnosis and the LAST
diagnosis were used for comparison.
Human papillomavirus genotyping and laser capture
microdissection
HPV genotyping of whole tissue sections (WTS) was done
using the analytically sensitive SPF10-PCR-DEIA-LiPA25 ver-
sion 1 system, genotyping 25 lr- and hrHPV types.24 The cau-
sative genotype of the highest graded lesion present on biopsy
was attributed to the genotype found in the WTS in case of a
single infection in ≥ AIN1 biopsies. From biopsies in which
multiple HPV genotypes were found, the worst lesion was
selected for LCM to identify the causative type of this worst
lesion. Laser-captured worst lesions were analysed according
to the same HPV testing algorithm (SPF10).25
Immunohistochemistry
FFPE sections 4-lm thick were used for IHC staining with
p16INK4a and panHPV E4 using heat-induced epitope retrieval
with citrate buffer (Dako/Agilent Technologies, Santa Clara,
CA, U.S.A.) and a primary mouse monoclonal antibody anti-
p16INK4a clone E6H4 [Ventana Medical Systems Inc. (Roche
Diagnostics), Mannheim, Germany], and XR-E4-1 (Labo Bio-
medical Products BV, Rijswijk, the Netherlands). The panHPV
E4 antibody has been found to be reactive against at least HPV
genotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 67 and 70.17,22 Reactivity was visualized using
the EnVision Detection System (Dako/Agilent Technologies).
All slides were scored jointly by two expert pathologists for
p16 grade and E4 positivity, resulting in an immunoscore for
each marker.
p16INK4a immunohistochemistry
p16 immunostaining was classified as no staining (grade 0),
patchy p16 positivity (grade 1), diffuse p16 positivity restricted
to the lower one-third of the epithelium (grade 2), diffuse p16
positivity restricted to the lower two-thirds of the epithelium
(grade 3), or diffuse staining above the lower two-thirds up to
full-thickness staining (grade 4). In the evaluation of p16 scores
in relation to LAST classification of HSILs, diffuse p16 staining
(grade 2, 3 or 4) was considered positive.
Human papillomavirus E4 immunohistochemistry
PanHPV E4 immunoreactivity in the worst lesion was scored
as negative (score 0); focal: restricted to groups of a few cells
in the upper layers of the epithelium (score 1); and extensive:
upper half of the epithelium or more (score 2).17 Any E4 pos-
itivity (score 1 or 2) in the highest-grade lesion identified was
considered E4 positive. E4 positivity at the edge of a high-
grade lesion adjacent to a low-grade lesion or normal epithe-
lium was considered negative as in previous studies.22
Statistical analyses
Results were analysed using IBM SPSS Statistics version 220
for Windows (IBM Corp., Armonk, NY, U.S.A.). Data were
presented as absolute numbers and percentages. Percentages
were compared using the v2-test, and the level of statistical
significance was set at P < 005.
Results
In 183 biopsies from 108 patients, classified by LAST recom-
mendations applied by two expert pathologists, there were 37
normal, 60 LSILs and 86 HSILs as the worst lesions seen in
the biopsies. Expert HE consensus diagnosis using the AIN
classification was negative in 37 biopsies, AIN1 in 67 biopsies,
AIN2 in 43 biopsies and AIN3 in 36 biopsies. Table 1 com-
pares consensus AIN diagnoses with LAST diagnoses.
Immunohistochemical marker scoring
Results of p16 and E4 scoring of the worst areas of lesions in
different grades of AIN and SILs are shown in Tables 2 and 3.
The p16 score increased with lesion severity, with 83% of all
negative/AIN1 lesions (86 of 104) and 93% of negative/LSILs
(90 of 97) by LAST criteria showing no or patchy p16 stain-
ing. Of all ≥ AIN2 lesions, 89% (70 of 79) showed diffuse
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p16 staining above the lower one-third of the epithelium,
with 58% of AIN2 showing diffuse staining above the lower
two-thirds of the epithelium and 78% of AIN3 showing this
pattern. Using the LAST diagnosis of HSIL, only 1% (one of
86) showed patchy staining and 67% showed staining of
more than two-thirds of the epithelium.
E4 was negative in 100% of the normal biopsies, while 49%
of the AIN1 lesions (33 of 67) scored positive for E4. In AIN2,
56% of the lesions (24 of 43) were E4 positive and only one of
the 36 AIN3 lesions was E4 positive (3%) (P < 0001). When
using the LAST diagnosis, 26 of 60 LSILs (43%) and 32 of 86
HSILs (37%) were E4 positive (P = 046).
Human papillomavirus genotyping of the worst lesion
Single human papillomavirus infections
WTS (n = 183) were tested for HPV positivity and genotyped,
resulting in nine HPV-negative biopsies, 120 with a single HPV
genotype, of which 11 could not be genotyped (type X), and 54
with multiple genotypes present. The most frequently found HPV
genotype as a single infection was HPV6 (22 biopsies from 18
patients), followed by HPV16 (17 biopsies from 16 patients).
The causative genotype of the worst lesion present on
biopsy was attributed to the genotype found in the WTS in
case of a single infection in ≥ LSIL biopsies. Biopsies in which
no abnormal epithelium was found were excluded when iden-
tifying the causative type (19 of 120 single infections).
Multiple human papillomavirus infections
The causative type of the worst lesion in the 45 of 54 biopsies
with multiple infections was identified using LCM: nine biop-
sies contained normal anal epithelium only and were not fur-
ther analysed. The worst diagnosis of the remaining 45
biopsies was LSIL in 10 and HSIL in 35.
In total, a causative genotype was identified for 139 of 146
worst lesions and seven worst lesions were HPV positive but
could not be genotyped (type X). Table S1 (see Supporting
Information) shows the causative genotype in LSILs and HSILs
according to LAST diagnosis. Most LSILs were caused by lrHPV
(51 of 60, 85%) and most HSILs were caused by hrHPV (80
of 86, 93%, P < 0001), making an important distinction
between disease caused by lrHPV and by hrHPV.
Immunohistochemical staining patterns in lesions caused
by low- and high-risk human papillomavirus infections
The relationship between expression patterns of p16 and E4,
and causative HPV infection (lr- or hrHPV) was explored in rela-
tion to the LAST classification. Of the 57 lesions caused by
lrHPV, most showed an extensive patchy p16 staining pattern
(51 of 57, 90%) as shown in Figure 1, but six of 57 (11%)
showed diffuse p16 staining and were called HSILs. Lesions
caused by hrHPV showed a diffuse p16 staining pattern in 96%
of cases (85 of 89) (example in Fig. 2), and the remaining four
lesions showed a less extensive patchy staining pattern that was
restricted to the lower one-third of the epithelium. There was
no significant difference in E4 positivity between lesions caused
by lr- or hrHPV (E4 positivity: 22 of 57, 386% of lesions and
36 of 89, 404% of lesions, respectively, P = 082).
Table 1 Consensus diagnosis based on haematoxylin and eosin
staining using anal intraepithelial neoplasia (AIN) classification











Normal (n = 37) 37 (100) 0 0
AIN1 (n = 67) 0 56 (84) 11 (16)
AIN2 (n = 43) 0 4 (9) 39 (91)
AIN3 (n = 36) 0 0 36 (100)
Values are presented as n (%). LSIL, low-grade squamous
intraepithelial lesion; HSIL, high-grade SIL.
Table 2 p16INK4a scores in biopsies with different grades of anal intraepithelial neoplasia (AIN) by (a) consensus diagnosis and (b) Lower









(grade 2) ≤ Lower 2/3 (grade 3) > Lower 2/3 (grade 4)
Normal (n = 37) 20 (54) 16 (43) 1 (3) 0 0
AIN1 (n = 67) 1 (2) 49 (73) 4 (6) 7 (10) 6 (9)
AIN2 (n = 43) 0 4 (9) 3 (7) 11 (26) 25 (58)
AIN3 (n = 36) 0 1 (3) 1 (3) 6 (16) 28 (78)
(b) LAST diagnosis
p16 score
Negative (grade 0) Patchy (grade 1) ≤ Lower 1/3 (grade 2) ≤ Lower 2/3 (grade 3) > Lower 2/3 (grade 4)
Normal (n = 37) 20 (54) 16 (43) 1 (3) 0 0
LSIL (n = 60) 1 (2) 53 (88) 3 (5) 2 (3) 1 (2)
HSIL (n = 86) 0 1 (1) 5 (6) 22 (26) 58 (67)
Values are presented as n (%). LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade SIL.
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Table 4 shows the relation between p16 grade and E4 posi-
tivity in HSILs. There was one HSIL/AIN3 that had a patchy
p16 staining pattern, E4 negativity, and that was associated
with lrHPV. In the group of 85 HSILs that showed diffuse p16
positivity (≥ grade 2), there was a gradual decrease in E4 pos-
itivity from 60% (three of five) in HSILs showing p16 in the
lower one-third of the epithelium, to 41% (nine of 22) of
HSILs with p16 in the lower two-thirds and 35% (20 of 58)
in HSILs with p16 in more than two-thirds of the epithelium.
Discussion
This study showed that anal HSILs are heterogeneous, with
p16 and E4 making complementary, specific contributions to
defining the nature of an anal SIL. This enabled separation of
HSILs into those expressing both HPV E4 and p16, and those
expressing only p16. Increasing p16 expression was associated
with decreasing E4 expression. This variation was partly
reflected in the HE grading of AIN2 and AIN3.
p16 is a surrogate marker for the activity of hrHPV E7,26
which has transforming activity, but is also necessary for produc-
tion of viral particles. Its grade increases with lesion severity both
between LSILs and HSILs and with AIN grading. Its expression
pattern can largely separate lrHPV infections from hrHPV infec-
tions. Importantly, there were two distinct extensive patterns of
p16 staining, one being extensive patchy staining caused by
lrHPV infection and the other being diffuse p16 staining caused
by hrHPV infection. Recognizing the difference is important for
accurate classification of lesions. Several studies have found simi-
lar differences in expression of p16 between lr- and hrHPV
infection in cervical biopsies.27,28 Some patchy p16 expression is
also seen in certain physiological states such as metaplasia in the
cervix,29 but this is not as extensive as seen here.
E4 indicates the continued presence of completion of the life
cycle of HPV,19 which is found in both LSILs and HSILs. We
showed that hrHPV-positive HSILs with evidence of transforma-
tion as defined by diffuse p16 positivity are not homogeneous:
almost half show evidence of continuing completion of the HPV
life cycle, and productive infection as indicated by E4 expression.
We demonstrated that as p16 expression increased there
was a decrease of E4 positivity with increasing p16 grade.
Scoring of p16 and E4 IHC markers has previously been
shown to be reproducible and separates productive from more
advanced transforming infections.18,30 This provides a more
reliable potential approach to selecting patients for treatment
than does AIN/SIL diagnosis.
In this set of biopsies (176 of 183 from HIV+ MSM,
962%), few LSILs (nine of 60, 15%) were associated with
hrHPV, and only six of 86 HSILs (7%) were associated with
lrHPV. In the case of HIV+ MSM, the clinical implications of
HSILs associated with lrHPV are uncertain.31 Such HSILs/AIN2
lesions showing extensive patchy p16 staining in the absence
of E4 might represent an abortive, nonproductive lrHPV infec-
tion overexpressing HPV E7 and not completing the HPV life
cycle. The mechanism for strong patchy expression of p16 in
lrHPV infections is unclear.32
This study supports the suggestion that anal HSILs represent
a highly heterogeneous group, consisting of productive lesions
that are potentially self-limiting as well as transforming lesions
with a risk of progression to cancer.14 It also supports the use
of p16 as a surrogate for hrHPV identification.
Scoring based on immunomarkers has a better inter- and
intraobserver agreement compared with grading based on
morphology,18,33 and opens up the possibility of reproducible
subclassification of the heterogeneity of HSILs. In our study,
37% of HSILs according to our LAST diagnosis showed E4 pos-
itivity as evidence of productive infections. Previous research
in CIN showed that a dual biomarker approach using E4 and
p16 can distinguish HPV-associated CIN1 from other patholo-
gies and may be used to divide the CIN2 group according to
the extent of life-cycle deregulation.17 The percentage of E4-
positive HSILs (37%) is in line with the percentage of E4-posi-
tive CIN2 lesions found by van Baars et al. (435%).18
Based on biomarker expression used in this study, E4-posi-
tive hrHPV-associated HSILs expressing p16 and lrHPV-asso-
ciated SILs with extensive patchy p16 warrant investigation of
a ‘wait and see’ management policy rather than immediate
Table 3 E4 scores (negative vs. focal or extensive positivity) in biopsies with different grades of anal intraepithelial neoplasia (AIN) by (a)
consensus diagnosis and (b) Lower Anogenital Squamous Terminology (LAST) diagnosis
(a) Consensus diagnosis
E4 score
Negative (grade 0) Focal positivity (grade 1) Extensive positivity (grade 2)
Normal (n = 37) 37 (100) 0 0
AIN1 (n = 67) 34 (51) 7 (10) 26 (39)
AIN2 (n = 43) 19 (44) 8 (19) 16 (37)
AIN3 (n = 36) 35 (97) 0 1 (3)
(b) LAST diagnosis
E4 score
Negative (grade 0) Focal positivity (grade 1) Extensive positivity (grade 2)
Normal (n = 37) 37 (100) 0 0
LSIL (n = 60) 34 (57) 5 (8) 21 (35)
HSIL (n = 86) 54 (63) 10 (12) 22 (25)
Values are presented as n (%). LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade SIL.
© 2019 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2019)
p16/E4 grading in low- and high-risk HPV in anal SIL, A. Leeman et al. 5
treatment. Studies of serial biopsies and well documented clin-
ical follow-up studies are necessary to establish the optimal
use of IHC markers in routine practice and to optimize patient
selection for treatment.
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